CA2491128A1 - Treatment for eye disorder - Google Patents
Treatment for eye disorder Download PDFInfo
- Publication number
- CA2491128A1 CA2491128A1 CA002491128A CA2491128A CA2491128A1 CA 2491128 A1 CA2491128 A1 CA 2491128A1 CA 002491128 A CA002491128 A CA 002491128A CA 2491128 A CA2491128 A CA 2491128A CA 2491128 A1 CA2491128 A1 CA 2491128A1
- Authority
- CA
- Canada
- Prior art keywords
- membrane
- molecule
- bruch
- diffusion
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000030533 eye disease Diseases 0.000 title claims abstract description 35
- 238000011282 treatment Methods 0.000 title abstract description 24
- 210000001775 bruch membrane Anatomy 0.000 claims abstract description 139
- 210000001519 tissue Anatomy 0.000 claims abstract description 76
- 239000012528 membrane Substances 0.000 claims abstract description 44
- 210000004379 membrane Anatomy 0.000 claims abstract description 40
- 238000009792 diffusion process Methods 0.000 claims abstract description 34
- 230000003213 activating effect Effects 0.000 claims abstract description 26
- 238000002604 ultrasonography Methods 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 98
- 208000002780 macular degeneration Diseases 0.000 claims description 54
- 235000018102 proteins Nutrition 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 40
- -1 o-nitrobenzyl Chemical group 0.000 claims description 38
- 102000004190 Enzymes Human genes 0.000 claims description 35
- 108090000790 Enzymes Proteins 0.000 claims description 35
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 29
- 238000012014 optical coherence tomography Methods 0.000 claims description 29
- 230000004913 activation Effects 0.000 claims description 22
- 150000002632 lipids Chemical class 0.000 claims description 22
- 230000004075 alteration Effects 0.000 claims description 19
- 238000002347 injection Methods 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 17
- 230000027455 binding Effects 0.000 claims description 15
- 125000006239 protecting group Chemical group 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- 239000007850 fluorescent dye Substances 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims description 10
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 claims description 10
- IRFHMTUHTBSEBK-QGZVFWFLSA-N tert-butyl n-[(2s)-2-(2,5-difluorophenyl)-3-quinolin-3-ylpropyl]carbamate Chemical compound C1([C@H](CC=2C=C3C=CC=CC3=NC=2)CNC(=O)OC(C)(C)C)=CC(F)=CC=C1F IRFHMTUHTBSEBK-QGZVFWFLSA-N 0.000 claims description 10
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 claims description 10
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 claims description 9
- 235000001014 amino acid Nutrition 0.000 claims description 9
- 229940024606 amino acid Drugs 0.000 claims description 9
- 239000003599 detergent Substances 0.000 claims description 9
- 239000002502 liposome Substances 0.000 claims description 9
- 230000004382 visual function Effects 0.000 claims description 8
- 238000012800 visualization Methods 0.000 claims description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 7
- 239000002961 echo contrast media Substances 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 208000027073 Stargardt disease Diseases 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 230000000593 degrading effect Effects 0.000 claims description 6
- 239000000975 dye Substances 0.000 claims description 6
- 208000027653 severe early-childhood-onset retinal dystrophy Diseases 0.000 claims description 6
- 108090001060 Lipase Proteins 0.000 claims description 5
- 102000004882 Lipase Human genes 0.000 claims description 5
- 239000004367 Lipase Substances 0.000 claims description 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 5
- 108010055297 Sterol Esterase Proteins 0.000 claims description 5
- 102000000019 Sterol Esterase Human genes 0.000 claims description 5
- 235000019421 lipase Nutrition 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- 229940009098 aspartate Drugs 0.000 claims description 4
- 201000006321 fundus dystrophy Diseases 0.000 claims description 4
- 229930195712 glutamate Natural products 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- 229920002101 Chitin Polymers 0.000 claims description 3
- 102000012479 Serine Proteases Human genes 0.000 claims description 3
- 108010022999 Serine Proteases Proteins 0.000 claims description 3
- 102000005600 Cathepsins Human genes 0.000 claims description 2
- 108010084457 Cathepsins Proteins 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 abstract description 26
- 238000006731 degradation reaction Methods 0.000 abstract description 24
- 239000000126 substance Substances 0.000 abstract description 20
- 210000001525 retina Anatomy 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 9
- 210000003161 choroid Anatomy 0.000 abstract description 2
- 230000003413 degradative effect Effects 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 12
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 10
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 10
- 206010025421 Macule Diseases 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000004393 visual impairment Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 8
- 230000008719 thickening Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 201000004569 Blindness Diseases 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 230000002186 photoactivation Effects 0.000 description 5
- 238000002428 photodynamic therapy Methods 0.000 description 5
- 206010029113 Neovascularisation Diseases 0.000 description 4
- 208000022873 Ocular disease Diseases 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 210000005166 vasculature Anatomy 0.000 description 4
- 208000022758 Sorsby fundus dystrophy Diseases 0.000 description 3
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 108091008695 photoreceptors Proteins 0.000 description 3
- 150000004032 porphyrins Chemical class 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000004300 dark adaptation Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000011325 dry age related macular degeneration Diseases 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000005043 peripheral vision Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000649 photocoagulation Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 210000004911 serous fluid Anatomy 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001585 trabecular meshwork Anatomy 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- HXBMIQJOSHZCFX-UHFFFAOYSA-N 1-(bromomethyl)-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1CBr HXBMIQJOSHZCFX-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000004297 night vision Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- CTRLRINCMYICJO-UHFFFAOYSA-N phenyl azide Chemical compound [N-]=[N+]=NC1=CC=CC=C1 CTRLRINCMYICJO-UHFFFAOYSA-N 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000012713 reactive precursor Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940061392 visudyne Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39350502P | 2002-07-02 | 2002-07-02 | |
| US60/393,505 | 2002-07-02 | ||
| PCT/US2003/020672 WO2004004757A1 (en) | 2002-07-02 | 2003-07-01 | Treatment for eye disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2491128A1 true CA2491128A1 (en) | 2004-01-15 |
Family
ID=30115595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002491128A Abandoned CA2491128A1 (en) | 2002-07-02 | 2003-07-01 | Treatment for eye disorder |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7381404B2 (enExample) |
| EP (1) | EP1539222A1 (enExample) |
| JP (1) | JP2005532393A (enExample) |
| CN (1) | CN1678342A (enExample) |
| CA (1) | CA2491128A1 (enExample) |
| WO (1) | WO2004004757A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005532393A (ja) * | 2002-07-02 | 2005-10-27 | ザ・リージェンツ・オブ・ジ・ユニバーシティ・オブ・カリフォルニア | 眼の障害についての処置 |
| US7727544B2 (en) | 2004-05-07 | 2010-06-01 | The Regents Of The University Of California | Treatment of myopia |
| US7654540B2 (en) * | 2004-06-18 | 2010-02-02 | Bose Corporation | Electromechanical transducing |
| JP2008510529A (ja) * | 2004-08-27 | 2008-04-10 | エレックス メディカル プロプライエタリー リミテッド | 選択的眼科レーザ治療 |
| JP2006195240A (ja) * | 2005-01-14 | 2006-07-27 | Fuji Photo Film Co Ltd | 断層画像化装置 |
| US7668342B2 (en) | 2005-09-09 | 2010-02-23 | Carl Zeiss Meditec, Inc. | Method of bioimage data processing for revealing more meaningful anatomic features of diseased tissues |
| US7768652B2 (en) * | 2006-03-16 | 2010-08-03 | Carl Zeiss Meditec, Inc. | Methods for mapping tissue with optical coherence tomography data |
| WO2007143796A1 (en) * | 2006-06-15 | 2007-12-21 | Seagull Ip Pty Ltd | A delivery system and process |
| DE102006030382A1 (de) * | 2006-06-29 | 2008-01-03 | Carl Zeiss Meditec Ag | Verfahren und Vorrichtung zur optischen Detektion am Auge |
| AT504159A1 (de) * | 2006-08-16 | 2008-03-15 | Marlyn Nutraceuticals Inc | Verwendung von proteasen |
| US8043235B2 (en) * | 2006-08-22 | 2011-10-25 | Schwartz Donald N | Ultrasonic treatment of glaucoma |
| AU2007308749B2 (en) | 2006-10-25 | 2013-02-14 | Alpharet Pty Ltd | Retinal regeneration |
| ES2666300T3 (es) * | 2007-02-15 | 2018-05-03 | The Uab Research Foundation | Método de fotoblanqueamiento mejorado |
| JP5656627B2 (ja) * | 2007-05-30 | 2015-01-21 | エレックス アールアンドディー プロプライエタリー リミテッドＥｌｌｅｘ Ｒ＆Ｄ Ｐｔｙ Ｌｔｄ | 網膜活性化レーザ装置 |
| EP2309919B1 (en) | 2008-07-10 | 2019-03-06 | Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO | Functional optical coherent imaging |
| KR101018785B1 (ko) * | 2008-11-28 | 2011-03-03 | 삼성전기주식회사 | 전자기 밴드갭 구조물 및 회로 기판 |
| US8609729B2 (en) * | 2009-04-15 | 2013-12-17 | Sucampo Ag | Method for treating macular degeneration |
| US9226654B2 (en) | 2011-04-29 | 2016-01-05 | Carl Zeiss Meditec, Inc. | Systems and methods for automated classification of abnormalities in optical coherence tomography images of the eye |
| EP2840957B1 (en) | 2012-04-27 | 2024-01-03 | Stryker European Operations Limited | Optical coherent imaging medical device and method |
| CA2914780C (en) | 2012-07-10 | 2020-02-25 | Aimago S.A. | Perfusion assessment multi-modality optical medical device |
| CN103656621A (zh) * | 2013-12-02 | 2014-03-26 | 黄丽娜 | 一种新型鼠神经生长因子玻璃体腔注射给药系统及其应用 |
| CN103705551A (zh) * | 2013-12-02 | 2014-04-09 | 黄丽娜 | 一种新型白蒺藜皂苷玻璃体腔注射给药系统及其应用 |
| CN103877430B (zh) * | 2014-04-20 | 2016-04-20 | 赵华 | 一种治疗黄斑变性的药物及制备方法 |
| CN107735015B (zh) | 2015-05-07 | 2021-09-10 | 史赛克欧洲运营有限公司 | 使用彩色图像传感器的用于组织的激光散斑成像的方法和系统 |
| US11273072B2 (en) | 2017-01-13 | 2022-03-15 | Gyroscope Therapeutics Limited | Suprachoroidal injection device |
| CA3052765C (en) * | 2017-02-09 | 2022-07-12 | Altregen Co.,Ltd. | Composition comprising composite extract from ginseng/red ginseng and sea cucumber as effective ingredient for preventing or treating bruch's membrane hypofunction-related disease |
| CN110730903B (zh) * | 2017-06-08 | 2023-02-28 | 优志旺电机株式会社 | 光谱测定方法、光谱测定装置以及宽波段脉冲光源单元 |
| US20180360655A1 (en) * | 2017-06-16 | 2018-12-20 | Michael S. Berlin | Methods and systems for oct guided glaucoma surgery |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US220245A (en) * | 1879-10-07 | Improvement in provision-safes | ||
| US6A (en) * | 1836-08-10 | Thomas Blanchard | Machine for forming end pieces of plank blocks for ships | |
| US87985A (en) * | 1869-03-16 | Improved rotary metal-cotter | ||
| US91229A (en) * | 1869-06-15 | Improvement in feeding-device for machines for combing- cotton | ||
| US138329A (en) * | 1873-04-29 | Improvement in wheel-plows | ||
| US4944944A (en) * | 1987-11-19 | 1990-07-31 | Oklahoma Medical Research Foundation | Dietary compositions and methods using bile salt-activated lipase |
| US20030087985A1 (en) | 1990-10-15 | 2003-05-08 | Hubbell Jeffrey A. | Gels for encapsulation of biological materials |
| US5462990A (en) * | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
| US5410016A (en) * | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| US5626863A (en) * | 1992-02-28 | 1997-05-06 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| US5468505A (en) | 1992-02-28 | 1995-11-21 | Board Of Regents, The University Of Texas System | Local delivery of fibrinolysis enhancing agents |
| US5573934A (en) * | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
| NZ249770A (en) * | 1992-02-28 | 1996-09-25 | Univ Texas | Biodegradable, polymerisable, substantially water soluble macromer comprising at least one water soluble region, at least one degradable region and at least two free radical polymerisable regions separated by at least one degradable region |
| US20040138329A1 (en) | 1992-04-20 | 2004-07-15 | Board Of Regents Of The University Of Texas System | Gels for encapsulation of biological materials |
| US5310764A (en) * | 1992-05-08 | 1994-05-10 | Steven Baranowitz | Treatment of age related macular degeneration with beta-carotene |
| US5800373A (en) * | 1995-03-23 | 1998-09-01 | Focal, Inc. | Initiator priming for improved adherence of gels to substrates |
| US5458505A (en) * | 1994-02-03 | 1995-10-17 | Prager; Jay H. | Lamp cooling system |
| US5798349A (en) * | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
| US5935942A (en) * | 1994-12-14 | 1999-08-10 | Zeimer; Ran | Selective and non-invasive visualization or treatment of vasculature |
| EP0815177B1 (en) * | 1995-03-23 | 2007-08-08 | Genzyme Corporation | Redox and photoinitiator systems for priming for improved adherence of gels to substrates |
| US6461640B1 (en) * | 1995-12-08 | 2002-10-08 | Board Of Regents, The University Of Texas System | Local delivery of fibrinolysis enhancing agents |
| US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| US6059828A (en) * | 1996-03-18 | 2000-05-09 | Peyman; Gholam A. | Macular indentor for use in the treatment of subretinal neovascular membranes |
| US6153211A (en) * | 1997-07-18 | 2000-11-28 | Infimed, Inc. | Biodegradable macromers for the controlled release of biologically active substances |
| US6128525A (en) * | 1997-07-29 | 2000-10-03 | Zeng; Haishan | Apparatus and method to monitor photodynamic therapy (PDT) |
| EP1027016A4 (en) * | 1997-10-27 | 2006-03-08 | Univ California | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REFERRING RETINAL RIPPLE |
| US6472541B2 (en) | 1998-11-20 | 2002-10-29 | The Regents Of The University Of California | Protecting groups with increased photosensitivities |
| US6858229B1 (en) * | 1999-04-26 | 2005-02-22 | California Institute Of Technology | In situ forming hydrogels |
| DE19920158A1 (de) * | 1999-04-29 | 2000-11-02 | Univ Schiller Jena | Verfahren und Anordnung zur Bestimmung von Fluorophoren an Objekten, insbesondere am lebenden Augenhintergrund |
| US6271233B1 (en) * | 1999-08-10 | 2001-08-07 | Ciba Vision Corporation | Method for treating ocular neovascular diseases |
| US6267954B1 (en) * | 1999-11-24 | 2001-07-31 | Universite De Paris V Rene-Descartes | Intraocular transplantation of encapsulated cells |
| WO2001051087A2 (en) | 2000-01-12 | 2001-07-19 | Light Sciences Corporation | Novel treatment for eye disease |
| US7011952B2 (en) * | 2000-02-22 | 2006-03-14 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| US7291673B2 (en) | 2000-06-02 | 2007-11-06 | Eidgenossiche Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| EP1461028A4 (en) | 2001-12-07 | 2007-07-25 | Univ California | TREATMENT FOR AGE-RELATED MACULAR AGENCY |
| JP2005532393A (ja) * | 2002-07-02 | 2005-10-27 | ザ・リージェンツ・オブ・ジ・ユニバーシティ・オブ・カリフォルニア | 眼の障害についての処置 |
| US20040199130A1 (en) * | 2003-04-03 | 2004-10-07 | Chornenky Victor I. | Apparatus and method for treatment of macular degeneration |
-
2003
- 2003-07-01 JP JP2004519718A patent/JP2005532393A/ja active Pending
- 2003-07-01 WO PCT/US2003/020672 patent/WO2004004757A1/en not_active Ceased
- 2003-07-01 EP EP03763073A patent/EP1539222A1/en not_active Withdrawn
- 2003-07-01 US US10/611,013 patent/US7381404B2/en not_active Expired - Fee Related
- 2003-07-01 CA CA002491128A patent/CA2491128A1/en not_active Abandoned
- 2003-07-01 CN CNA038208113A patent/CN1678342A/zh active Pending
-
2008
- 2008-05-23 US US12/126,100 patent/US8298521B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1678342A (zh) | 2005-10-05 |
| WO2004004757A8 (en) | 2004-10-07 |
| US7381404B2 (en) | 2008-06-03 |
| WO2004004757A1 (en) | 2004-01-15 |
| US20050048044A1 (en) | 2005-03-03 |
| US8298521B2 (en) | 2012-10-30 |
| EP1539222A1 (en) | 2005-06-15 |
| JP2005532393A (ja) | 2005-10-27 |
| US20080286255A1 (en) | 2008-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8298521B2 (en) | Treatment for eye disorder | |
| US20030171320A1 (en) | Methods for treating ocular neovascular diseases | |
| US6984655B1 (en) | Photodynamic therapy for selectively closing neovasa in eyeground tissue | |
| Costa et al. | Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization | |
| Ozdemir et al. | Regression of serous macular detachment after intravitreal triamcinolone acetonide in patients with diabetic macular edema | |
| Costa et al. | Indocyanine green-mediated photothrombosis as a new technique of treatment for persistent central serous chorioretinopathy | |
| JP2007536272A (ja) | 近視の処置法 | |
| JP2005535691A (ja) | 加齢性黄斑変性を有する患者における視力の保護のための酢酸アネコルタブの使用 | |
| Rechtman et al. | An update on photodynamic therapy in age-related macular degeneration | |
| Ciarnella et al. | Intravitreal ranibizumab and laser photocoagulation in the management of idiopathic juxtafoveolar retinal telangiectasia type 1: a case report | |
| Spaide | Central serous chorioretinopathy | |
| Moshfeghi et al. | Ocular vascular thrombosis following tin ethyl etiopurpurin (SnET2) photodynamic therapy: time dependencies | |
| AU2003253767A1 (en) | Treatment for eye disorder | |
| Singh et al. | The use of dye in ophthalmology | |
| JP2021522283A (ja) | 分子ピンセットによるリポフスチンの凝集の阻害 | |
| KR20050021375A (ko) | 안질환의 치료 방법 | |
| JP2004530645A (ja) | 特定の眼疾患の処置方法 | |
| Gohto et al. | Accumulation of photosensitizer ATX-S10 (Na) in experimental corneal neovascularization | |
| EP4186524A1 (en) | Prevention and/or treatment of eye disease by collagen fiber crosslinking | |
| Hill et al. | Photodynamic therapy for antifibrosis in a rabbit model of filtration surgery | |
| Serebryakov et al. | Alternative approach to laser methods of treating vascular pathologies of the eye | |
| Lobanovskaya | Central serous chorioretinopathy | |
| Kupersmith et al. | The blood-ocular barrier | |
| WO2006107598A2 (en) | Conjugates of photoactive compound and a bulking group for enhancing photodynamic therapy | |
| Karacorlu et al. | Photodynamic therapy with delayed light application for the treatment of bilateral subfoveal choroidal neovascularization in age-related macular degeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |